Xceleron and Sanofi-Aventis Sign Deal to Address Challenges in Exploratory Clinical Development
News Jun 12, 2007
Xceleron has announced that, following signature of a Master Services Agreement with Sanofi-Aventis Deutschland GmbH, a number of studies are underway to assess the human metabolism of novel compounds in early clinical development. This work utilises Xceleron’s ultra-sensitive Accelerator Mass Spectrometry (AMS) technology platform.
This latest deal adds to Xceleron’s growing client list of major organisations – including 15 of the world’s top 20 pharma companies.
Xceleron’s foundation in 1997 was supported by GSK, Novartis, Pfizer and Janssen (now Johnson & Johnson). Notably after many years of working with Xceleron to explore the potential of AMS, GSK now have 2 AMS machines of their own - focused specifically on similar kinds of metabolite profiling studies to those now being undertaken by Sanofi-Aventis.
SCIEX Announces Joint Venture with Zhenjang Dian Diagnostics in ChinaNews
Leading diagnostics companies combine to address diagnostic and wellness testing in China.READ MORE
Long-Lasting Issues from Inflexible ClogsNews
Researchers used osteobiography and paleopathology methods as well as stable isotope analysis and mass spectrometry on a group of skeletons, to analyse diet, disease and overall health. This revealed wooden clogs were likely to blame for injuries to the individual's feet.READ MORE
Heavy Nitrogen Molecules Reveal Planetary-Scale Tug-of-WarNews
Thanks to a one-of-a-kind mass spectrometer, researchers were able to count rare molecules in the atmosphere that contain only heavy isotopes of nitrogen. This has revealed a planetary-scale tug-of-war between life, the deep Earth and the upper atmosphere that is expressed in atmospheric nitrogen.